InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions VANCOUVER, British Columbia, June 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and...

InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV Study will use delta-9 dominant THCV manufactured by InMed’s subsidiary BayMedicaAssesses key health outcomes for energy, focus, appetite and weight/BMI Provides valuable evidence-based data on...

InMed Commercializes Cannabidivarin (CBDV), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector Expands rare cannabinoid portfolio beyond current CBC and CBTReleases White Paper outlining research into the therapeutic potential of CBDV VANCOUVER, British Columbia and SOUTH SAN FRANCISCO,...

InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector CBT is the first of several rare cannabinoid launches planned for the first half of 2022; includes CBDV and THCVExpands the Company’s rare cannabinoid product portfolio, which also includes...

The Power of Ultra Rare Doug's Varin™ Cannabis Formulation Now Available at Dispensaries Statewide in California Oakland, May 22, 2019 (GLOBE NEWSWIRE) -- Cannabis users who are seeking to unleash the power of THCV got some good news today as California Cannabinoids, Inc., the maker of Doug’s Varin™ announced...